Guided Therapeutics (GTHP) 0.3300 $GTHP
Guided Therapeutics Announces Initial $200,000 Investment from Turkish Distributor, ITEM Medical Technologies Group
Business Wire - Mon Sep 08, 7:40AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that its Turkish distributor, ITEM Medical Technologies Group, referred to as ITEM, has committed to invest $200,000 in a private placement of Guided Therapeutics' common stock.
Guided Therapeutics to Present at Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10th
Business Wire - Thu Sep 04, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) developer of the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, today announced that it will be a featured presenter at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at the New York Palace Hotel in New York City.
Guided Therapeutics Initiates Cervical Cancer Screening Trial for LuViva(R) Advanced Cervical Scan
Business Wire - Tue Aug 19, 7:02AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it will begin enrollment this week in a multi-center clinical trial to expand claims for the LuViva(R) Advanced Cervical Scan to include front-line screening for cervical cancer.
Guided Therapeutics Reports Second Quarter 2014 Results
Business Wire - Wed Aug 13, 3:07PM CDT
--Submitted amended PMA for LuViva(R) Advanced Cervical Scan
Guided Therapeutics to Report Second Quarter 2014 Results and Hold Conference Call
Business Wire - Thu Jul 31, 2:11PM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its second quarter ended June 30, 2014 on Wednesday, August 13, 2014, after the market closes.
Guided Therapeutics Files PMA Amendment with FDA for LuViva(R) Advanced Cervical Scan
Business Wire - Fri Jul 25, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has filed an amendment to its premarket approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the LuViva(R) Advanced Cervical Scan.
Guided Therapeutics Granted Additional Key Patent for LuViva(R) Advanced Cervical Scan
Business Wire - Thu Jul 17, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that U.S. Patent and Trademark Office granted a new patent with 22 claims that support the technology behind the LuViva(R) Advanced Cervical Scan.
Guided Therapeutics' LuViva(R) Advanced Cervical Scan Awarded Mexican Regulatory Approval
Business Wire - Thu Jul 10, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that LuViva(R) Advanced Cervical Scan was approved for sale in Mexico by the Federal Commission for Protection against Health Risks (COFEPRIS).
Guided Therapeutics Second Quarter Sales to Reach $200,000; Update Timing for Amended PMA Application for LuViva(R) Advanced Cervical Scan
Business Wire - Wed Jul 02, 12:22PM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today provided anticipated sales results for its second quarter ended June 30, 2014 and also provided updated timing regarding the submittal of its amendment to its premarket approval (PMA) application for the LuViva(R) Advanced Cervical Scan.
Gene S. Cartwright of Guided Therapeutics, Inc (GTHP)-OTC bought Shares of GTHP
M2 - Thu Jun 19, 9:40AM CDT
Reported by InsiderCow.com at 2014-06-18 19:03:00 ET
Guided Therapeutics' LuViva(R) Advanced Cervical Scan Wins Prestigious Medical Design Award
Business Wire - Thu Jun 12, 7:01AM CDT
The LuViva(R) Advanced Cervical Scan was chosen as best designed new medical device of 2014 at the 17th Annual Medical Device Excellence Awards (MDEA) ceremony held Wednesday, June 11, 2014, in conjunction with the MD&M East event at the Jacob K. Javits Convention Center in New York. LuViva, a newly introduced product for the early detection of disease that leads to cervical cancer, is manufactured and sold by Guided Therapeutics, Inc. (OTCBB:GTHP) (OTCQB:GTHP).
Guided Therapeutics Submits Request for Face to Face Meeting with FDA; Receives Notification on PMA Extension for LuViva(R) Advanced Cervical Scan
Business Wire - Thu Mar 27, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company has submitted a letter requesting a face-to-face meeting with the U.S. Food and Drug Administration (FDA) in the next 60 to 90 days. This letter is in response to the September 6, 2013 letter that the company received from the FDA. Additionally, the FDA has granted the company its requested 180 day extension on the PMA filing to allow time for the meeting to occur.
Guided Therapeutics Reports Fourth Quarter and 2013 Results
Business Wire - Wed Mar 26, 3:44PM CDT
--LuViva(R) Advanced Cervical Scan momentum building with key opinion leaders; increasing number of product evaluations
HPV Screening Beneficial for Guided Therapeutics' LuViva(R) Advanced Cervical Scan in Developed Countries; No Anticipated Impact in Developing Countries
Business Wire - Tue Mar 18, 7:05AM CDT
The March 12, 2014, recommendation by a U.S. Food and Drug Administration (FDA) panel to use human papillomavirus (HPV) testing as an alternative to Pap testing for screening of women for cervical cancer has the potential to increase the need for the LuViva(R) Advanced Cervical Scan in developed countries, according to Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP). As part of its CE Mark, LuViva is already approved for use in the European Union as a triage test to be used after a positive HPV test and/or a positive Pap test.
Guided Therapeutics to Report Fourth Quarter 2013 Results and Hold Conference Call
Business Wire - Wed Mar 05, 2:40PM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its fourth quarter ended December 31, 2013 on Wednesday, March 26, 2014, after the market closes.
New Clinical Study Results of Guided Therapeutics' LuViva(R) Advanced Cervical Scan to be Presented by Key Opinion Leaders at Top International Medical Conference
Business Wire - Tue Feb 18, 7:05AM CST
The Secretary General of the International Federation for Cervical Pathology and Colposcopy (IFCPC), Dr. James Bentley, will present results of a new clinical study of the LuViva(R) Advanced Cervical Scan at the 15th World Congress for Cervical Pathology and Colposcopy, being held May 26 - 30 in London. The LuViva, a non-invasive device used to detect cervical disease instantly at the point of care, is a product of Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP).
2014 Analysis of the US Hospital Cancer Diagnostics Market
M2 - Thu Feb 13, 3:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/g5hk8t/2014_analysis_of) has announced the addition of the "2014 Analysis of the US Hospital Cancer Diagnostics Market" report to their offering. This new report contains 533 pages, 43 tables, and presents a comprehensive analysis of the US hospital cancer diagnostics market, including: - Major issues pertaining to the French hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. - Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. - Test volume and sales forecasts for 40 cancer diagnostic procedures performed in French hospitals. - Current instrumentation technologies and feature comparison of leading analyzers. - Sales and market shares of leading suppliers. - Emerging diagnostic technologies and their potential market applications. - Product development opportunities. - Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. - Business opportunities and strategic recommendations for suppliers. Key Topics Covered: Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology B. Major Current And Emerging Cancer Diagnostic Tests C. Instrumentation Review And Market Needs D. Current and Emerging Technologies US A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Growth and Major Suppliers Major Product Development Opportunities A. Reagent Kits and Test Systems/Panels B. Instrumentation C. Computers, Software and Automation D. Auxiliary Products Design Criteria for Decentralized Testing Products Alternative Market Penetration Strategies A. Internal Development B. Collaborative Arrangements C. University Contracts D. Distribution Strategies 1. Marketing Approaches 2. Product Complexity 3. Customer Preference 4. Established Suppliers 5. Emerging Suppliers 6. Major Types of Distributors 7. Market Segmentation Factor Potential Market Entry Barriers and Risks A. Market Maturity B. Cost Containment C. Competition D. Technological Edge and Limitations E. Patent Protection F. Regulatory Constraints G. Decentralized Testing Market Challenges Companies Mentioned: - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/g5...nalysis_of
2014 Analysis of the World Cancer Diagnostic Testing Market: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities
M2 - Mon Feb 10, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/r66j8d/2014_analysis_of) has announced the addition of the "2014 Analysis of the World Cancer Diagnostic Testing Market: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities" report to their offering. This new report contains 1,200 pages, 450 tables and provides forecasts for 40 tumor markers by country and market segment, as well as sales and market shares for reagent and instrument suppliers. The report is available by region, country, section, market segment and individual test: Regions: Global, Europe Countries: France, Germany, Italy, Japan, Spain, UK, USA Sections: Assays, Competitors, Instrumentation, Technologies Market Segments: Hospitals (France, Germany, Italy, Japan, Spain, UK, USA), Personalized Testing Tests: AFP, Beta-2 Microglobulin,CA Tumor Markers, CEA, Cell Surface Markers, Occult Blood, PAP, Pap Smear/HPV, PSA To purchase a DataPack that includes (test volumes, sales forecasts, supplier shares) please E-mail us. Key Topics Covered: Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology B. Major Current And Emerging Cancer Diagnostic Tests C. Instrumentation Review And D. Current and Emerging Technologies Competitive Profiles - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - Biomedical Diagnostics - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila - bioMerieux For more information visit http://www.researchandmarkets.com/research/r6...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Niko Receives Conversion Notice
Marketwire - Thu Jan 09, 5:01PM CST
Niko Resources Ltd. (TSX: NKO) announces that on January 8, 2014, it received a notice of conversion in accordance with the terms of the amended and restated 7% senior unsecured notes due July 13, 2014 (the "Notes"
to convert approximately US$0.25 million of the Notes. The conversion will result in the issuance of 120,904 common shares to a holder of the Notes and the outstanding principal balance of the Notes will be approximately US$8.3 million.
Guided Therapeutics Receives Additional Questions from FDA for LuViva(R) Advanced Cervical Scan
Business Wire - Mon Sep 09, 6:00AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company received additional questions from the U.S. Food and Drug Administration (FDA) regarding the pre-market approval application for the LuViva(R) Advanced Cervical Scan. FDA advised the company the PMA was not yet approvable in its current form and that the company needed to address these questions in order to place the PMA in approvable form.
Guided Therapeutics Announces Initial $200,000 Investment from Turkish Distributor, ITEM Medical Technologies Group
Business Wire - Mon Sep 08, 7:40AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that its Turkish distributor, ITEM Medical Technologies Group, referred to as ITEM, has committed to invest $200,000 in a private placement of Guided Therapeutics' common stock.
Guided Therapeutics to Present at Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10th
Business Wire - Thu Sep 04, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) developer of the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, today announced that it will be a featured presenter at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at the New York Palace Hotel in New York City.
Guided Therapeutics Initiates Cervical Cancer Screening Trial for LuViva(R) Advanced Cervical Scan
Business Wire - Tue Aug 19, 7:02AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it will begin enrollment this week in a multi-center clinical trial to expand claims for the LuViva(R) Advanced Cervical Scan to include front-line screening for cervical cancer.
Guided Therapeutics Reports Second Quarter 2014 Results
Business Wire - Wed Aug 13, 3:07PM CDT
--Submitted amended PMA for LuViva(R) Advanced Cervical Scan
Guided Therapeutics to Report Second Quarter 2014 Results and Hold Conference Call
Business Wire - Thu Jul 31, 2:11PM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its second quarter ended June 30, 2014 on Wednesday, August 13, 2014, after the market closes.
Guided Therapeutics Files PMA Amendment with FDA for LuViva(R) Advanced Cervical Scan
Business Wire - Fri Jul 25, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has filed an amendment to its premarket approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the LuViva(R) Advanced Cervical Scan.
Guided Therapeutics Granted Additional Key Patent for LuViva(R) Advanced Cervical Scan
Business Wire - Thu Jul 17, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that U.S. Patent and Trademark Office granted a new patent with 22 claims that support the technology behind the LuViva(R) Advanced Cervical Scan.
Guided Therapeutics' LuViva(R) Advanced Cervical Scan Awarded Mexican Regulatory Approval
Business Wire - Thu Jul 10, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that LuViva(R) Advanced Cervical Scan was approved for sale in Mexico by the Federal Commission for Protection against Health Risks (COFEPRIS).
Guided Therapeutics Second Quarter Sales to Reach $200,000; Update Timing for Amended PMA Application for LuViva(R) Advanced Cervical Scan
Business Wire - Wed Jul 02, 12:22PM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today provided anticipated sales results for its second quarter ended June 30, 2014 and also provided updated timing regarding the submittal of its amendment to its premarket approval (PMA) application for the LuViva(R) Advanced Cervical Scan.
Gene S. Cartwright of Guided Therapeutics, Inc (GTHP)-OTC bought Shares of GTHP
M2 - Thu Jun 19, 9:40AM CDT
Reported by InsiderCow.com at 2014-06-18 19:03:00 ET
Guided Therapeutics' LuViva(R) Advanced Cervical Scan Wins Prestigious Medical Design Award
Business Wire - Thu Jun 12, 7:01AM CDT
The LuViva(R) Advanced Cervical Scan was chosen as best designed new medical device of 2014 at the 17th Annual Medical Device Excellence Awards (MDEA) ceremony held Wednesday, June 11, 2014, in conjunction with the MD&M East event at the Jacob K. Javits Convention Center in New York. LuViva, a newly introduced product for the early detection of disease that leads to cervical cancer, is manufactured and sold by Guided Therapeutics, Inc. (OTCBB:GTHP) (OTCQB:GTHP).
Guided Therapeutics Submits Request for Face to Face Meeting with FDA; Receives Notification on PMA Extension for LuViva(R) Advanced Cervical Scan
Business Wire - Thu Mar 27, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company has submitted a letter requesting a face-to-face meeting with the U.S. Food and Drug Administration (FDA) in the next 60 to 90 days. This letter is in response to the September 6, 2013 letter that the company received from the FDA. Additionally, the FDA has granted the company its requested 180 day extension on the PMA filing to allow time for the meeting to occur.
Guided Therapeutics Reports Fourth Quarter and 2013 Results
Business Wire - Wed Mar 26, 3:44PM CDT
--LuViva(R) Advanced Cervical Scan momentum building with key opinion leaders; increasing number of product evaluations
HPV Screening Beneficial for Guided Therapeutics' LuViva(R) Advanced Cervical Scan in Developed Countries; No Anticipated Impact in Developing Countries
Business Wire - Tue Mar 18, 7:05AM CDT
The March 12, 2014, recommendation by a U.S. Food and Drug Administration (FDA) panel to use human papillomavirus (HPV) testing as an alternative to Pap testing for screening of women for cervical cancer has the potential to increase the need for the LuViva(R) Advanced Cervical Scan in developed countries, according to Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP). As part of its CE Mark, LuViva is already approved for use in the European Union as a triage test to be used after a positive HPV test and/or a positive Pap test.
Guided Therapeutics to Report Fourth Quarter 2013 Results and Hold Conference Call
Business Wire - Wed Mar 05, 2:40PM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its fourth quarter ended December 31, 2013 on Wednesday, March 26, 2014, after the market closes.
New Clinical Study Results of Guided Therapeutics' LuViva(R) Advanced Cervical Scan to be Presented by Key Opinion Leaders at Top International Medical Conference
Business Wire - Tue Feb 18, 7:05AM CST
The Secretary General of the International Federation for Cervical Pathology and Colposcopy (IFCPC), Dr. James Bentley, will present results of a new clinical study of the LuViva(R) Advanced Cervical Scan at the 15th World Congress for Cervical Pathology and Colposcopy, being held May 26 - 30 in London. The LuViva, a non-invasive device used to detect cervical disease instantly at the point of care, is a product of Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP).
2014 Analysis of the US Hospital Cancer Diagnostics Market
M2 - Thu Feb 13, 3:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/g5hk8t/2014_analysis_of) has announced the addition of the "2014 Analysis of the US Hospital Cancer Diagnostics Market" report to their offering. This new report contains 533 pages, 43 tables, and presents a comprehensive analysis of the US hospital cancer diagnostics market, including: - Major issues pertaining to the French hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. - Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. - Test volume and sales forecasts for 40 cancer diagnostic procedures performed in French hospitals. - Current instrumentation technologies and feature comparison of leading analyzers. - Sales and market shares of leading suppliers. - Emerging diagnostic technologies and their potential market applications. - Product development opportunities. - Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. - Business opportunities and strategic recommendations for suppliers. Key Topics Covered: Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology B. Major Current And Emerging Cancer Diagnostic Tests C. Instrumentation Review And Market Needs D. Current and Emerging Technologies US A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Growth and Major Suppliers Major Product Development Opportunities A. Reagent Kits and Test Systems/Panels B. Instrumentation C. Computers, Software and Automation D. Auxiliary Products Design Criteria for Decentralized Testing Products Alternative Market Penetration Strategies A. Internal Development B. Collaborative Arrangements C. University Contracts D. Distribution Strategies 1. Marketing Approaches 2. Product Complexity 3. Customer Preference 4. Established Suppliers 5. Emerging Suppliers 6. Major Types of Distributors 7. Market Segmentation Factor Potential Market Entry Barriers and Risks A. Market Maturity B. Cost Containment C. Competition D. Technological Edge and Limitations E. Patent Protection F. Regulatory Constraints G. Decentralized Testing Market Challenges Companies Mentioned: - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/g5...nalysis_of
2014 Analysis of the World Cancer Diagnostic Testing Market: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities
M2 - Mon Feb 10, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/r66j8d/2014_analysis_of) has announced the addition of the "2014 Analysis of the World Cancer Diagnostic Testing Market: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities" report to their offering. This new report contains 1,200 pages, 450 tables and provides forecasts for 40 tumor markers by country and market segment, as well as sales and market shares for reagent and instrument suppliers. The report is available by region, country, section, market segment and individual test: Regions: Global, Europe Countries: France, Germany, Italy, Japan, Spain, UK, USA Sections: Assays, Competitors, Instrumentation, Technologies Market Segments: Hospitals (France, Germany, Italy, Japan, Spain, UK, USA), Personalized Testing Tests: AFP, Beta-2 Microglobulin,CA Tumor Markers, CEA, Cell Surface Markers, Occult Blood, PAP, Pap Smear/HPV, PSA To purchase a DataPack that includes (test volumes, sales forecasts, supplier shares) please E-mail us. Key Topics Covered: Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology B. Major Current And Emerging Cancer Diagnostic Tests C. Instrumentation Review And D. Current and Emerging Technologies Competitive Profiles - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - Biomedical Diagnostics - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila - bioMerieux For more information visit http://www.researchandmarkets.com/research/r6...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Niko Receives Conversion Notice
Marketwire - Thu Jan 09, 5:01PM CST
Niko Resources Ltd. (TSX: NKO) announces that on January 8, 2014, it received a notice of conversion in accordance with the terms of the amended and restated 7% senior unsecured notes due July 13, 2014 (the "Notes"
to convert approximately US$0.25 million of the Notes. The conversion will result in the issuance of 120,904 common shares to a holder of the Notes and the outstanding principal balance of the Notes will be approximately US$8.3 million. Guided Therapeutics Receives Additional Questions from FDA for LuViva(R) Advanced Cervical Scan
Business Wire - Mon Sep 09, 6:00AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company received additional questions from the U.S. Food and Drug Administration (FDA) regarding the pre-market approval application for the LuViva(R) Advanced Cervical Scan. FDA advised the company the PMA was not yet approvable in its current form and that the company needed to address these questions in order to place the PMA in approvable form.
